meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - breast cancer (mBC)
1
cervical cancer (CC)
classical Hodgkin lymphoma (cHL)
antibody–drug conjugate
trastuzumab deruxtecan
versus all
vs chemotherapy
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
progression or deaths (PFS)
deaths (OS)
metastatic/advanced - breast cancer (mBC)
metastatic/advanced - breast cancer (mBC)
versus chemotherapy
trastuzumab deruxtecan vs. chemotherapy
1
1.0
better
0.3
5.0
100 %
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open